259 related articles for article (PubMed ID: 33648463)
21. Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.
Cohen JB; Zain JM; Kahl BS
Am Soc Clin Oncol Educ Book; 2017; 37():512-525. PubMed ID: 28561694
[TBL] [Abstract][Full Text] [Related]
22. SOX11, a key oncogenic factor in mantle cell lymphoma.
Beekman R; Amador V; Campo E
Curr Opin Hematol; 2018 Jul; 25(4):299-306. PubMed ID: 29738333
[TBL] [Abstract][Full Text] [Related]
23. The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study.
Cencini E; Sicuranza A; Fabbri A; Marzano C; Pacelli P; Caroni F; Raspadori D; Bocchia M
Leuk Lymphoma; 2023 Oct; 64(10):1634-1642. PubMed ID: 37424258
[TBL] [Abstract][Full Text] [Related]
24. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.
Salek D; Vesela P; Boudova L; Janikova A; Klener P; Vokurka S; Jankovska M; Pytlik R; Belada D; Pirnos J; Moulis M; Kodet R; Michal M; Janousova E; Muzik J; Mayer J; Trněný M
Leuk Lymphoma; 2014 Apr; 55(4):802-10. PubMed ID: 23772666
[TBL] [Abstract][Full Text] [Related]
25. Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages.
Koh YW; Shin SJ; Park C; Yoon DH; Suh C; Huh J
Hematol Oncol; 2014 Dec; 32(4):178-86. PubMed ID: 24910369
[TBL] [Abstract][Full Text] [Related]
26. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
[TBL] [Abstract][Full Text] [Related]
27. Expression and role of MIG/CXCR3 axis in mantle cell lymphoma.
Zhu MX; Wan WL; Hong Y; Wang YF; Dong F; Jing HM
Exp Cell Res; 2020 Dec; 397(2):112365. PubMed ID: 33197439
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.
Goswami RS; Atenafu EG; Xuan Y; Waldron L; Reis PP; Sun T; Datti A; Xu W; Kuruvilla J; Good DJ; Lai R; Church AJ; Lam WS; Baetz T; Lebrun DP; Sehn LH; Farinha P; Jurisica I; Bailey DJ; Gascoyne RD; Crump M; Kamel-Reid S
J Clin Oncol; 2013 Aug; 31(23):2903-11. PubMed ID: 23835716
[TBL] [Abstract][Full Text] [Related]
29. Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.
Cohen JB; Ruppert AS; Heerema NA; Andritsos LA; Jones JA; Porcu P; Baiocchi R; Christian BA; Byrd JC; Flynn J; Penza S; Devine SM; Blum KA
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):278-285.e1. PubMed ID: 25660723
[TBL] [Abstract][Full Text] [Related]
30. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E;
Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239
[TBL] [Abstract][Full Text] [Related]
31. Elevated SOX11 mRNA level correlates with favorable prognosis in mantle cell lymphoma.
He J; Xi Y; Gao N; Xu E; Xie L; Chang J; Liu J
J BUON; 2019; 24(4):1679-1685. PubMed ID: 31646825
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
von Hohenstaufen KA; Conconi A; de Campos CP; Franceschetti S; Bertoni F; Margiotta Casaluci G; Stathis A; Ghielmini M; Stussi G; Cavalli F; Gaidano G; Zucca E
Br J Haematol; 2013 Aug; 162(4):465-73. PubMed ID: 23808798
[TBL] [Abstract][Full Text] [Related]
33. Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma.
Wang L; Mo S; Li X; He Y; Yang J
Cancer Biol Med; 2020 Aug; 17(3):726-739. PubMed ID: 32944402
[No Abstract] [Full Text] [Related]
34. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
35. Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy.
McKnight AJ; Savage DA; Patterson CC; Sadlier D; Maxwell AP
BMC Med Genet; 2007 Feb; 8():5. PubMed ID: 17319955
[TBL] [Abstract][Full Text] [Related]
36.
Vera-Lozada G; Minnicelli C; Segges P; Stefanoff G; Kristcevic F; Ezpeleta J; Tapia E; Niedobitek G; Barros MHM; Hassan R
Oncoimmunology; 2018; 7(5):e1389821. PubMed ID: 29721365
[TBL] [Abstract][Full Text] [Related]
37. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
Balsas P; Palomero J; Eguileor Á; Rodríguez ML; Vegliante MC; Planas-Rigol E; Sureda-Gómez M; Cid MC; Campo E; Amador V
Blood; 2017 Jul; 130(4):501-513. PubMed ID: 28533307
[TBL] [Abstract][Full Text] [Related]
38. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.
Yamasaki S; Chihara D; Kim SW; Izutsu K; Iwato K; Fukuda T; Uchida N; Amano I; Nakazawa H; Kuroda J; Hashimoto H; Ichinohe T; Kanda Y; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2018 Aug; 97(8):1445-1452. PubMed ID: 29610968
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism in Brazilian breast cancer patients: association with susceptibility, clinicopathological features, and interaction with TGFB1 haplotypes.
Vitiello GAF; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
Breast Cancer Res Treat; 2019 Nov; 178(1):207-219. PubMed ID: 31364002
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.
Cerhan JR; Wang S; Maurer MJ; Ansell SM; Geyer SM; Cozen W; Morton LM; Davis S; Severson RK; Rothman N; Lynch CF; Wacholder S; Chanock SJ; Habermann TM; Hartge P
Blood; 2007 Jun; 109(12):5439-46. PubMed ID: 17327408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
